<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>6(5)</volume><submitter>Ressing M</submitter><funding>Deutsche Krebshilfe</funding><pubmed_abstract>&lt;h4>Background&lt;/h4>Epidemiological research on late effects of therapy shows the necessity to aggregate chemotherapy agents to substance classes. This requires using conversion factors by substance classes.&lt;h4>Aims&lt;/h4>The aim of this study was to identify previously used conversion factors from the literature, to present a novel approach for additional factors, and to compare these approaches.&lt;h4>Methods and results&lt;/h4>A literature review was performed, which identified two main principles of deriving conversion factors: effect-equivalence and equimolar. Thirty-five articles presenting effect equivalence-based factors in the widest sense were found in the literature. Ten articles presented the equimolar approach which can be applied to almost all chemotherapy substances. Based on a compr</pubmed_abstract><journal>Cancer reports (Hoboken, N.J.)</journal><pagination>e1811</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10172172</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Equivalent doses for anticancer agents used in pediatric oncology: A literature review and evaluation of a novel approach for conversion factors.</pubmed_title><pmcid>PMC10172172</pmcid><pubmed_authors>Erdmann F</pubmed_authors><pubmed_authors>Voigt M</pubmed_authors><pubmed_authors>Spix C</pubmed_authors><pubmed_authors>Mahmoudpour SH</pubmed_authors><pubmed_authors>Muller C</pubmed_authors><pubmed_authors>Langer T</pubmed_authors><pubmed_authors>Blettner M</pubmed_authors><pubmed_authors>Ressing M</pubmed_authors><pubmed_authors>Calaminus G</pubmed_authors><pubmed_authors>Becker C</pubmed_authors><pubmed_authors>Kaiser M</pubmed_authors><pubmed_authors>Kaatsch P</pubmed_authors></additional><is_claimable>false</is_claimable><name>Equivalent doses for anticancer agents used in pediatric oncology: A literature review and evaluation of a novel approach for conversion factors.</name><description>&lt;h4>Background&lt;/h4>Epidemiological research on late effects of therapy shows the necessity to aggregate chemotherapy agents to substance classes. This requires using conversion factors by substance classes.&lt;h4>Aims&lt;/h4>The aim of this study was to identify previously used conversion factors from the literature, to present a novel approach for additional factors, and to compare these approaches.&lt;h4>Methods and results&lt;/h4>A literature review was performed, which identified two main principles of deriving conversion factors: effect-equivalence and equimolar. Thirty-five articles presenting effect equivalence-based factors in the widest sense were found in the literature. Ten articles presented the equimolar approach which can be applied to almost all chemotherapy substances. Based on a compr</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 May</publication><modification>2025-04-22T00:26:25.36Z</modification><creation>2025-04-05T19:37:39.785Z</creation></dates><accession>S-EPMC10172172</accession><cross_references><pubmed>36975206</pubmed><doi>10.1002/cnr2.1811</doi></cross_references></HashMap>